-
2 weeks ago | 
neurologylive.com | Amit Bar-Or |Isabella Ciccone
WATCH TIME: 4 minutes“There's nothing more gratifying than when your peers basically are saying, ‘You seem to be on the right track.’ I think that's the main message—that all of us work hard, passionately—and so it's really humbling and very rewarding to have that recognition.”The John Dystel Prize for Multiple Sclerosis Research, a notable honor, is jointly awarded by the National MS Society and the American Academy of Neurology.
-
Jan 15, 2025 | 
octnews.org | Amit Bar-Or
January 15, 2025 | Neurology | Queen Mary University of London, Ruhr-University Bochum, University of BaselBackground
People with MS show abnormal thinning of the retinal layers, which is associated with clinical disability and brain atrophy, and is a potential surrogate marker of neurodegeneration and treatment effects.
-
Jul 4, 2024 | 
nature.com | Jiwon Oh |Amit Bar-Or
Immunological profiling has revealed biological signatures of multiple sclerosis (MS) that could help with early, accurate diagnosis of the disease and with identifying disease subtypes that could inform treatment decisions. The findings are important steps along the path towards precision medicine for people with MS.
-
Mar 17, 2024 | 
neurologylive.com | Amit Bar-Or
WATCH TIME: 5 minutes"BTK inhibitors targets B cells and myeloid cells, including microglia. When one thinks of the updated framework of the immunology of MS, we think of immune cell interactions in the periphery involving B cells, myeloid cells, and T cells. They all talk to each other and cross regulate each other.”Evobrutinib (Merck KGaA/EMD Serono) is an investigational Bruton’s tyrosine kinase (BTK) inhibitor in development for patients with multiple sclerosis (MS).
-
Dec 21, 2023 | 
neurologylive.com | Jiwon Oh |Amit Bar-Or
December 21, 2023Experts conclude their discussion with pearls on the treatment of smouldering multiple sclerosis and prospective advances in medicine.
-
Dec 21, 2023 | 
neurologylive.com | Jiwon Oh |Amit Bar-Or
December 21, 2023Experts discuss holistic approaches to care for patients with multiple sclerosis (MS), including lifestyle changes and managing comorbidities. TranscriptJiwon Oh, MD, PhD: You mentioned earlier when we were talking about the various drivers of smoldering MS [multiple sclerosis], you mentioned the role of things like comorbidities in aging. And so right now it does sound like you do talk to your patients about smoldering MS.
-
Dec 19, 2023 | 
neurologylive.com | Amit Bar-Or |Jiwon Oh
TranscriptJiwon Oh, MD, PhD: Now that we have a better idea of some of the drivers of smoldering MS [multiple sclerosis], and there [are] many different complexities that you’ve highlighted that I’m sure we’ll learn more about in the coming years, but we actually have ways we can maybe even image some of the drivers of smoldering MS. What are some emerging therapeutic drug classes that may play a role in the coming years?
-
Dec 19, 2023 | 
neurologylive.com | Jiwon Oh |Amit Bar-Or
December 19, 2023Experts explain the biological drivers underlying smouldering multiple sclerosis (MS) and how it might impact treatment modalities. TranscriptJiwon Oh, MD, PhD: I think you’ve highlighted 2 of the key biological processes that we think drive smoldering MS [multiple sclerosis], which include chronic active lesions and subpial inflammation and demyelination.
-
Dec 7, 2023 | 
neurologylive.com | Jiwon Oh |Amit Bar-Or
December 7, 2023Experts describe our current understanding of the pathology of multiple sclerosis (MS). TranscriptJiwon Oh, MD, PhD: You mentioned a ray of hope, potential new treatments, but before we get to that, I’m just going to segue into talking a little bit more about underlying mechanisms of smoldering MS [multiple sclerosis].
-
Dec 7, 2023 | 
neurologylive.com | Jiwon Oh |Amit Bar-Or
TranscriptJiwon Oh, MD, PhD: So, can I ask Amit, just one last clinical question. Do you talk to your patients about smoldering MS? I was talking about earlier how, you know, this is really the hot topic and everybody at clinical and scientific meetings are talking about it, but is this a term that you use with patients and if you do, how do you describe it?
